Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Johnson & Johnson CEO Joaquin Duato said J&J will avoid the GLP-1 weight-loss drug race, instead emphasizing oncology and its large medical device business to diversify away from GLP-1 concentration risk. The piece contrasts Eli Lilly’s GLP-1 revenue dominance (nearly two-thirds of revenues) and higher valuation (P/E >40x) with J&J’s lower P/E (~29x) and higher dividend yield (2.1% vs 0.6%). Overall, the article argues J&J’s long-term, income-oriented profile is more attractive than staying in the GLP-1 spotlight.

Analysis

The setup is less about “anti-GLP-1” and more about what the market is paying for certainty. JNJ is being positioned as a lower-volatility cash compounding asset with multiple engines, while LLY’s valuation already discounts a long runway of obesity penetration and limited pricing erosion; that makes LLY more exposed to even small disappointments in refill rates, payer pushback, or incremental competition than its growth profile suggests. The key second-order effect is that healthcare capital is starting to bifurcate: investors will keep rewarding best-in-class growth, but they may increasingly prefer diversified incumbents where a single franchise cannot dominate the equity story.

For JNJ, the near-term upside is probably multiple stability rather than multiple expansion. If the market rotates toward defensives or higher-for-longer rates compress the premium on duration-heavy growth names, JNJ can rerate modestly as an earnings-quality and dividend anchor; the opposite is also true, and it would underperform sharply if obesity volumes keep compounding without visible slowing. Over 6-18 months, the more important question is whether JNJ’s oncology and device portfolio can reaccelerate enough to offset any perception that it is opting out of the fastest secular growth pool.

The contrarian view is that the market may be over-penalizing “non-participation” in GLP-1. A large pharma does not need exposure to every hot category if it can preserve pricing power and avoid concentration risk; that can actually support a higher quality-of-earnings multiple over time. The risk is that JNJ becomes a classic value trap if its non-GLP-1 growth engines fail to convert pipeline progress into visible revenue inflection within the next few quarters.

Key Decisions for Investors

• Long JNJ / short LLY as a relative-value pair for 3-6 months: thesis is valuation compression at LLY vs quality rerating/support at JNJ; fade if LLY guidance or prescription data re-accelerate materially.
• Use JNJ as a defensive healthcare hold into the next 1-2 earnings cycles; the trade is lower downside in a risk-off tape, with upside from dividend-support and multiple floor, not explosive growth.
• Avoid adding to LLY here unless you have conviction that obesity persistence and pricing will surprise positively for at least 2 more quarters; at >40x earnings, small misses can de-rate the stock 10-15% quickly.
• Watch NVO vs LLY relative performance as the best tell on whether the GLP-1 trade is becoming crowded; if both start to lag while JNJ holds up, rotate some healthcare exposure into JNJ/XLV defensives.
• Alert item: if JNJ does not show clear oncology or med-tech acceleration at the next update, the current ‘diversified compounder’ premium may be capped; below-market growth with only income support is not enough for sustained outperformance.